Company Analysis

Zevra Therapeutics, Inc. (ZVRA)

Nasdaq: ZVRA · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2008
Grade5.6
◀ Past 4.5● Present 5.8▶ Future 6.1
1 est.

Who runs Zevra Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Mcfarlane Neil F.
President and CEO. First filing Oct 2023, latest Oct 13, 2026, 5 filings in all.
Officers reporting now
7
of 14 people with a filing in the last fifteen months
Directors reporting now
7
27 people on the record since 2015
Officerssales are open-market, Oct 13, 2025 to Oct 13, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Mcfarlane Neil F.President and CEOOct 2023Oct 13, 20263 · $1.2M
Thompson RahsaanChief Legal & ComplianceJun 2024Aug 17, 20264 · $1.0M
Sangiovanni Timothy J.SVP, Finance & Corp ControllerFeb 2017May 29, 20262 · $0.00
Renz Justin ACFOMar 2026Mar 19, 2026none
Schafer JoshuaCCOJan 2023Feb 4, 20262 · $100,000
Quartel Adrian WChief Medical OfficerMar 2025Feb 2, 20261 · $0.00
Clifton R. LaduaneCFO & TreasurerApr 2015Jan 7, 2026none
Directorssales are open-market, Oct 13, 2025 to Oct 13, 2026
NameRoleFirst filingLatest filingSales, 12 months
Watton Corey MichaeldirectorMay 2023Aug 12, 20261 · $100,000
Anderson ThomasdirectorAug 2023Jun 18, 2026none
Calder Douglas WdirectorMay 2023Jun 18, 2026none
Secor AliciadirectorDec 2025Jun 18, 2026none
Seymour Tamara AdirectorAug 2021Jun 18, 2026none
Shih AlvindirectorFeb 2024Jun 18, 2026none
Bode John BdirectorMay 2023Mar 26, 2026none
Earlier names on the record19, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ZVRA · research, not advice